Comparing the current results to its competitors, Arvinas Inc reported Revenue increase in the 2 quarter 2026 by 1014.73 % year on year. The sales growth was above Arvinas Inc 's competitors' average revenue growth of 6.2 %, achieved in the same quarter.
Arvinas Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, which is characterized by rapid technological advancements and a strong focus on intellectual property. It faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. Competitors specifically engaged in research on chimeric small molecules for protein degradation include Accutar Biotechnology, Inc., C4 Therapeutics, Inc., Cullgen Inc., Foghorn Therapeutics, Inc., Kymera Therapeutics, Inc., Nurix Therapeutics, Inc., and Proteovant Therapeutics, Inc. The company's product candidates will compete with existing and future therapies, including biologic, pharmaceutical, and other treatment approaches. The industry is characterized by numerous patents and frequent patent infringement disputes.
June 21, 2024
Arvinas, a biopharmaceutical company focused on developing targeted protein degradation therapies, recently announced the presentation of preclinical data for two of its PROTAC investigational programs at various scientific conferences. The programs, targeting BCL6 and LRRK2 proteins, have shown promising results in treating certain diseases, including B-cell lymphoma.At the European Hematology Association 2024 Annual Congress, Arvinas presented data for its investigational drug ARV-393, which targets the BCL6 protein. BCL6 is a transcription factor that plays a crucial role in the development and function of B-cells. Dysregulation of BCL6 has been implicated in various forms of B-cell lymphoma, making it an...
May 9, 2024
Arvinas, Inc., a well-known American biopharmaceutical company, has announced its plans to present two posters featuring enriched clinical trial data on the investigational drug Vepdegestrant at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress. This crucial medical conference is set to take place from May 15 to 17, 2024, in Berlin, Germany.Vepdegestrant is an innovative PROTAC® estrogen receptor (ER) degrader currently being jointly developed by Arvinas and Pfizer. The drug is attracting industry and clinical attention for its potential in treating patients diagnosed with early or locally advanced, as well as metastatic ER+/human epidermal growth factor receptor 2 (HER2-) ...
April 11, 2024
Breaking: Arvinas Strikes Major Deal with Novartis for Prostate Cancer Treatment DevelopmentArvinas, a renowned biopharmaceutical company specializing in targeted protein degradation, has recently announced a groundbreaking agreement with global pharmaceutical giant Novartis. The partnership entails a global license agreement for the development and commercialization of PROTAC Androgen Receptor (AR) Protein Degrader ARV-766, an innovative treatment for prostate cancer.As part of this historic deal, Arvinas will receive a substantial upfront payment of $150 million for licensing ARV-766 and selling its preclinical AR-V7 program to Novartis. Moreover, the agreement includes the potential for Arvinas to earn up...
Arvinas and Pfizer have recently released interim data from a Phase 1b trial of Vepdegestrant, in combination with Palbociclib (IBRANCE), and have announced plans to expand the Vepdegestrant development program. The findings are highly promising, with an overall response rate of 42% and a median progression-free survival of 11.1 months in heavily pre-treated patients. These results, based on 48% of events after an 11-month median follow-up time, demonstrate the potential of Vepdegestrant when used in conjunction with Palbociclib. In comparison with its competitors, Arvinas Inc has also reported an impressive increase in revenue during the third quarter of 2023. The company experienced a robust year-...
Kalvista Pharmaceuticals Inc's business model primarily focuses on the development and commercialization of novel small molecule therapies for various diseases. They strive to discover and develop innovative treatments to address unmet medical needs, and aim to bring these therapies to market efficiently and effectively.
Immunome Inc is a biotechnology company that focuses on developing novel immunotherapies. Their business model revolves around leveraging their proprietary discovery engine to identify therapeutic antibodies for infectious diseases and cancer. By collaborating with partners and through their own clinical development efforts, they aim to bring these promising treatments to the market.
Oculis Holding Ag is a pharmaceutical company that specializes in developing and commercializing innovative ophthalmic treatments. Their business model revolves around conducting in-depth research and development to formulate eye medications that target various ocular diseases. They then seek regulatory approvals and form strategic partnerships to manufacture and distribute their products globally, aiming to improve eye health and provide effective treatment options for patients.
Third Harmonic Bio Inc's business model centers around developing and commercializing innovative therapeutic solutions through the utilization of bioinformatics and genomics.
Sources:
Arvinas Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Arvinas Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
